Uncategorized

Vertex’s Casgevy becomes first approved gene therapy for young kids with rare blood disorders

Published

on

The FDA approved the expansion of Casgevy, which had previously been greenlit for patients 12 and up, into a younger pediatric population under the agency’s Commissioner’s National Priority Voucher program.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version